Inactive Instrument

Press Releases Neon Therapeutics, Inc.

Equities

US64050Y1001

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

NEON THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	20-05-06	AQ
NEON THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	20-05-05	AQ
Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01	20-04-30	GL
Infinity Pharmaceuticals : Augments Board of Directors with Appointment of Richard Gaynor, M.D	20-03-18	AQ
NEON THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	20-03-02	AQ
NEON THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)	20-03-02	AQ
Neon Therapeutics : Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update	20-03-02	AQ
NEON THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Neon Therapeutics, Inc. - NTGN	20-01-28	BU
NEON THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	20-01-16	AQ
Neon Therapeutics : Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01	19-12-18	AQ
NEON THERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities (form 8-K)	19-11-20	AQ
Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs	19-11-20	GL
Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights	19-11-12	GL
Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting	19-11-08	GL
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens	19-09-05	GL
Neon Therapeutics Reports Second Quarter 2019 Financial Results	19-08-06	GL
Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers	19-07-15	GL
Neon Therapeutics to Present at Jefferies 2019 Healthcare Conference	19-06-03	GL
Neon Therapeutics Reports First Quarter 2019 Financial Results and Provides Clinical Update	19-05-13	GL
Neon Therapeutics Presents Updated Data from Ongoing Phase 1b NT-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01 at AACR 2019 Annual Meeting	19-03-31	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Neon Therapeutics, Inc.

Equities

US64050Y1001

Press Releases

Filters